Travoprost - Alcon
Alternative Names: AL 06221; AL-6221; Izba; Travatan; Travatan APS; Travatan Z; Travatanz; Travoprost advanced preservative system; Travoprost APSLatest Information Update: 15 Apr 2019
At a glance
- Originator Alcon
- Developer Alcon; Novartis
- Class Antiglaucomas; Eye disorder therapies; Prostaglandins; Small molecules
- Mechanism of Action Prostaglandin F2 alpha agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Open-angle glaucoma
- No development reported Ocular hypertension
Most Recent Events
- 09 Apr 2019 Novartis completed the spin-off of Alcon eye care devices business
- 27 Jan 2017 Novartis has patent protection for travoprost in Europe and Japan (Novartis 20-F filed in 2017)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Ocular-hypertension(In adolescents, In children, In infants) in Saudi Arabia (Ophthalmic, Drops)